Condition: Biliary Tract Cancer · Biliary Tract Neoplasms · Cholangiocarcinoma · Sponsor: Case Comprehensive Cancer Center
Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working. The treatment for patients whose advanced BTC either did not make the cancer better or is no longer working is a combination of chemotherapy drugs called FOLFOX which consists of fluorouracil and oxaliplatin. Studies have shown that other treatments may work better to treat advanced BTC. In this study, investigators want to see if treating patients with the drug combination of trifluridine/tipiracil (FTD/TPI) and another drug called oxaliplatin works better than FOLFOX for advanced BTC as second-line therapy. FTD/TPI are pills that are taken by mouth, whereas oxaliplatin is given intravenously (by IV).
This description comes directly from the study's public registry record.
Madison Conces, MD · 216-844-3951 · Madison.Conces@UHhospitals.org
Always discuss trial participation with your own doctor first.
| University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center | Cleveland, Ohio, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07146646